Pentanamide, N-methyl-N-(1-methylethyl)-

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Pentanamide, N-methyl-N-(1-methylethyl)-
• 英文别名: N-methyl-N-propan-2-ylpentanamide
• 化学式: C₉H₁₉NO
• mdl: MFCD18971700
• 分子量: 157.25
• InChiKey: JXQXUHOAHXDKQQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Modulators of muscarinic receptors
  申请人：Makings R. Lewis

  公开号：US20080015179A1

  公开（公告）日：2008-01-17

  The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

  本发明涉及肌胆碱受体调节剂。本发明还提供包含这种调节剂的组合物，并提供了用于治疗肌胆碱受体介导疾病的方法。
• RAS INHIBITORS
  申请人：Revolution Medicines, Inc.

  公开号：US20210130326A1

  公开（公告）日：2021-05-06

  The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

  该披露涉及大环化合物，以及能够抑制Ras蛋白质的药物组合物和蛋白质复合物，以及它们在治疗癌症中的用途。
• MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE
  申请人：Yale University

  公开号：US20190276459A1

  公开（公告）日：2019-09-12

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Burton's Tyrosine Kinase (BTK). In particular, the present disclosure is directed to bifunctional compounds. One end of a bifunctional compound includes a Von Hippel-Lindau, Cereblon, Inhibitors of Apotosis Proteins, or Mouse Double-Minute Homolog 2 ligand that binds to the respective E3 ubiquitin ligase. The other end of a bifunctional compound includes a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. Diseases or disorders that result from aggregation, accumulation, and/or overactivation of the target protein can be treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为Burton的酪氨酸激酶（BTK）的调节剂而有用。特别是，本公开是针对双功能化合物的。双功能化合物的一端包括Von Hippel-Lindau、Cereblon、Inhibitors of Apotosis Proteins或Mouse Double-Minute Homolog 2配体，该配体结合到相应的E3泛素连接酶。双功能化合物的另一端包括结合到目标蛋白质的部分，使目标蛋白质靠近泛素连接酶，以促进目标蛋白质的降解（和抑制）。本公开的化合物和组合物可用于治疗或预防由目标蛋白质的聚集、积累和/或过度活化引起的疾病或障碍。
• Modulators of BTK proteolysis and methods of use
  申请人：Yale University

  公开号：US11028088B2

  公开（公告）日：2021-06-08

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Burton's Tyrosine Kinase (BTK). In particular, the present disclosure is directed to bifunctional compounds. One end of a bifunctional compound includes a Von Hippel-Lindau, Cereblon, Inhibitors of Apotosis Proteins, or Mouse Double-Minute Homolog 2 ligand that binds to the respective E3 ubiquitin ligase. The other end of a bifunctional compound includes a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. Diseases or disorders that result from aggregation, accumulation, and/or overactivation of the target protein can be treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，这些化合物可用作伯顿酪氨酸激酶（BTK）的调节剂。特别是，本公开涉及双功能化合物。双功能化合物的一端包括与相应 E3 泛素连接酶结合的 Von Hippel-Lindau、Cereblon、抑制细胞凋亡蛋白或小鼠双敏同源物 2 配体。双功能化合物的另一端包括与靶蛋白结合的分子，这样靶蛋白就会被置于泛素连接酶附近，以实现对靶蛋白的降解（和抑制）。本公开的化合物和组合物可以治疗或预防由于靶蛋白的聚集、积累和/或过度激活而导致的疾病或失调。
• Indole and azaindole inhibitors of pad enzymes
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US11524959B1

  公开（公告）日：2022-12-13

  The present invention provides compounds of Formula (I) useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders, wherein each of Ring A, L, Q, R1, R2, R3, R4, R7, and R8 along with other variables are as defined herein.

  本发明提供了用作 PAD4 抑制剂的式 (I) 化合物、其组合物以及治疗 PAD4 相关疾病的方法，其中环 A、L、Q、R1、R2、R3、R4、R7 和 R8 中的每一个以及其他变量如本文所定义。